Sorrento Therapeutics Logo

Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

November 1, 2018

SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple myeloma patients at two clinical sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manufactured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study.

This study is the first US-based clinical trial targeting CD38 using an autologous CAR-T cell therapy. Details on the study can be found at: www.clinicaltrials.gov : NCT03464916. Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its' extensive immuno-oncology platforms, including key assets such as clinical stage fully human antibodies ("G-MAB™ library"), immuno-cellular therapies ("CAR-T"), antibody-drug conjugates ("ADC"), and oncolytic virus ("Seprehvir ®").

Sorrento's commitment to life-enhancing therapies is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin ("RTX") as well as to promote newly-launched ZTlido™. Resiniferatoxin is completing a Phase 1b trial in terminal cancer patients as well as in trial for osteoarthritis (OA) pain management. ZTlido was approved by the FDA on February 28, 2018 for the treatment of post-herpetic neuralgia.

For more information visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward looking statements include statements regarding the developments of and prospects for Sorrento's and its subsidiaries' and affiliates' products and technologies, including their respective antibody and CAR-T products and technologies (including, but not limited to, CD38 CAR-T cell therapy program), and expectations for Sorrento's and its subsidiaries', affiliates' and joint ventures' technologies and product candidates. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's, its subsidiaries', affiliates' and partners' technologies and prospects; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risks that prior clinical results and outcomes will not be replicated; risks of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks related to seeking regulatory approvals and conducting clinical trials; risks of supplying drug product; risks related to Sorrento's ability to leverage the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its strategies; risks related to Sorrento's M&A and licensing strategy; risks related to Sorrento's and its' subsidiaries' abilities to supply drug product; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2017, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations

Contact:

Alexis Nahama, DVM
Vice President, Corporate Development

Telephone: 1.858.203.4120
Email: mediarelations@sorrentotherapeutics.com

sorrento THERAPEUTICS

Source: Sorrento Therapeutics, Inc.